56 related articles for article (PubMed ID: 2858052)
1. Evaluation of an analogue of somatostatin (L363,586) in Alzheimer's disease.
Cutler NR; Haxby JV; Narang PK; May C; Burg C; Reines SA
N Engl J Med; 1985 Mar; 312(11):725. PubMed ID: 2858052
[No Abstract] [Full Text] [Related]
2. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study.
Amaducci L
Psychopharmacol Bull; 1988; 24(1):130-4. PubMed ID: 3290936
[No Abstract] [Full Text] [Related]
3. Choline in Alzheimer's disease.
Renvoize EB; Jerram T
N Engl J Med; 1979 Aug; 301(6):330. PubMed ID: 377082
[No Abstract] [Full Text] [Related]
4. Memory enhancement with oral physostigmine in Alzheimer's disease.
N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
[No Abstract] [Full Text] [Related]
5. [The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results].
Acierno G
Clin Ter; 1983 Apr; 105(2):135-45. PubMed ID: 6345054
[No Abstract] [Full Text] [Related]
6. Effects of 4-aminopyridine in elderly patients with Alzheimer's disease.
Wesseling H; Agoston S; Van Dam GB; Pasma J; DeWit DJ; Havinga H
N Engl J Med; 1984 Apr; 310(15):988-9. PubMed ID: 6366565
[No Abstract] [Full Text] [Related]
7. Somatostatin replacement therapy for Alzheimer dementia.
Mouradian MM; Blin J; Giuffra M; Heuser IJ; Baronti F; Ownby J; Chase TN
Ann Neurol; 1991 Oct; 30(4):610-3. PubMed ID: 1789687
[TBL] [Abstract][Full Text] [Related]
8. Lack of efficacy of hydergine in patients with Alzheimer's disease.
Thompson TL; Filley CM; Mitchell WD; Culig KM; LoVerde M; Byyny RL
N Engl J Med; 1990 Aug; 323(7):445-8. PubMed ID: 2082953
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of serotonergic system responsivity in Alzheimer's disease.
Lawlor BA; Mellow AM; Sunderland T; Hill JL; Murphy DL
Psychopharmacol Bull; 1988; 24(1):127-9. PubMed ID: 3290935
[No Abstract] [Full Text] [Related]
10. Multicenter trial of naloxone in Alzheimer's disease.
Henderson VW; Roberts E; Wimer C; Bardolph EL; Chui HC; Damasio AR; Eslinger PJ; Folstein MF; Schneider LS; Teng EL
Ann Neurol; 1989 Apr; 25(4):404-6. PubMed ID: 2653175
[TBL] [Abstract][Full Text] [Related]
11. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
Jenike MA; Albert MS; Heller H; Gunther J; Goff D
J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
[TBL] [Abstract][Full Text] [Related]
12. Neurotransmitter replacement therapy in Alzheimer's disease.
Mohr E; Mendis T; Rusk IN; Grimes JD
J Psychiatry Neurosci; 1994 Jan; 19(1):17-23. PubMed ID: 7908537
[TBL] [Abstract][Full Text] [Related]
13. A neuropsychological test battery for use in Alzheimer disease clinical trials.
Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
[TBL] [Abstract][Full Text] [Related]
14. Cortisol responses to cholinergic drugs in Alzheimer's disease.
Kumar V; Smith RC; Sherman KA; Ashford W; Murphy J; Giacobini E; Colliver J
Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):471-6. PubMed ID: 3069749
[TBL] [Abstract][Full Text] [Related]
15. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
Clipp EC; Moore MJ
Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
17. Donepezil for Alzheimer's disease.
Sparano N
J Fam Pract; 1998 May; 46(5):356. PubMed ID: 9597987
[No Abstract] [Full Text] [Related]
18. Noradrenergic intervention in Alzheimer's disease.
Crook T; Wilner E; Rothwell A; Winterling D; McEntee W
Psychopharmacol Bull; 1992; 28(1):67-70. PubMed ID: 1609045
[TBL] [Abstract][Full Text] [Related]
19. Preliminary experience on treatment of insulin-dependent diabetes mellitus with a long-acting somatostatin analogue (L363,586).
Bolli GB; Gottesman IS; Gerich JE
Horm Res; 1988; 29(2-3):95-8. PubMed ID: 2900206
[TBL] [Abstract][Full Text] [Related]
20. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
Wettstein A
Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
